RxDoctor Payments Data

Maher Saloum, MD

Internal Medicine · San Antonio, TXNPI 1487650487

Payments from drug & device makers

$514in general payments, 2019–2025

Across 53 payments — averaging $9.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$275
  • Sanofi-aventis U.S. LLC$117
  • Lilly USA, LLC$40
  • Astellas Pharma US Inc$36
  • Boehringer Ingelheim$19
  • Novartis$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$514 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,773
Medicare patients
80
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin94$132,314
TrulicityDulaglutide61$95,918
MounjaroTirzepatide57$67,264
OzempicSemaglutide35$47,600
EliquisApixaban32$46,472
Tresiba Flextouch U-200Insulin Degludec33$43,741
JanuviaSitagliptin Phosphate24$37,564
FarxigaDapagliflozin Propanediol32$31,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$23,771
Bydureon BciseExenatide Microspheres14$20,732
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$15,186
Humalog Kwikpen U-200Insulin Lispro17$15,028
XareltoRivaroxaban15$13,177
ShingrixVaricella-Zoster Ge/As01b/Pf44$9,268
AbrysvoRsv Vacc, Pref A And Pref B/Pf30$9,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$40$163,182118 claims
Boehringer IngelheimJardiance$19$132,31494 claims
PfizerEliquis, Abrysvo$13$55,56862 claims
Novo NordiskOzempic$275$47,60035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →